• Title/Summary/Keyword: Pancreatic tumors

Search Result 83, Processing Time 0.032 seconds

Littoral cell angiomas: Benign lesion with a penchant for visceral malignancies

  • Snigdha Gulati;Hoonbae Jeon;Adarsh Vijay
    • Annals of Hepato-Biliary-Pancreatic Surgery
    • /
    • v.27 no.1
    • /
    • pp.1-5
    • /
    • 2023
  • Littoral cell angiomas are rare vascular tumors of the spleen. Because of their rarity, unclear etiopathogenesis, and association with other malignancies, these tumors can pose diagnostic and therapeutic challenges. Due to paucity of published literature on this entity often limited to case reports, relevant data on this topic were procured and synthesized with the aid of a comprehensive Medline search in addition to oncologic, pathologic, radiologic, and surgical literature review on littoral cell angiomas. This article provides an in-depth review into postulated etiopathogenesis, pathology, clinical manifestations, associated malignancies, and prognostic features of littoral cell angiomas.

Feasibility Study of Cylindrically Diffusing 532 nm Wavelength for Treatment of Pancreatic Cancer

  • Park, Jin-Seok;Jeong, Seok;Lee, Don Haeng;Zheng, Hong-Mei;Kang, Hyun Wook;Bak, Jinoh;Choi, Jongman
    • Journal of the Korean Physical Society
    • /
    • v.73 no.11
    • /
    • pp.1619-1624
    • /
    • 2018
  • Laser ablation may provide a minimally invasive palliative treatment for pancreatic cancer. The aim of the current study was to assess the feasibility of a 532-nm laser equipped with a cylindrical light diffuser for the treatment of pancreatic cancer. Monolayers of BxPC-3 human pancreatic cancer cell were exposed to 532 nm laser light. Power levels of 5 - 7 W were used to uniformly target the entire cell colonies for 60 and 120 seconds. The cells were incubated for 24 hours after treatment and viabilities were determined by using a MTT assay. Laser ablation was performed by using the cylindrical light diffuser on six pancreatic tumor tissues obtained from pancreatic cancer xenograft mouse models, which were exposed to the 532 nm light at 5W or 7W for 10 to 30 seconds. In the in vitro study, the survival rates of the pancreatic cancer cells were reduced by 6.6% to 98.9% after the treatment, and the survival rates were reduced by increasing laser power and/or irradiation time. In the pancreatic tumor tissues, a homogenous circular ablation zone was observed in all tumors and the ablation distance induced by the laser irradiation showed to be constant from the diffuser to all directions (standard deviation, 0.3 - 1.3 mm). Ablation distance and area increased with increasing laser power and/or irradiation time. The 532 nm laser effectively killed pancreatic cancer cells, and the cylindrical light diffuser was found to be suitable for laser ablation as it provided uniform ablation in pancreatic cancer.

Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: Three case reports and a literature review

  • Min Kyu Sung;Woohyung Lee;Sarang Hong;Yejong Park;Bong Jun Kwak;Ki Byung Song;Jae Hoon Lee;Dae Wook Hwang;Song Cheol Kim
    • Annals of Hepato-Biliary-Pancreatic Surgery
    • /
    • v.27 no.1
    • /
    • pp.107-113
    • /
    • 2023
  • Mixed adenoneuroendocrine carcinoma is defined as a tumor with a mixture of adenocarcinoma components and neuroendocrine neoplasm components. Each of these two components of mixed adenoneuroendocrine carcinoma accounts for at least 30% of all tumors. Mixed adenoneuroendocrine carcinoma might be located in the ampulla of Vater, a very rare location compared to other organs. Thus, its treatment and prognosis plans have not been established yet. We report three cases of mixed adenoneuroendocrine carcinoma occurring in the ampulla of Vater. Each patient had a different clinical course. In general, difficulty in preoperative diagnosis, risk of early recurrence, and poor disease course were main hallmarks of mixed adenoneuroendocrine carcinoma arising from the ampulla of Vater. However, one patient in this case report survived although she did not receive adjuvant chemotherapy due to her old age. Therefore, it is important to establish a careful treatment strategy for mixed adenoneuroendocrine carcinoma arising from the ampulla of Vater.

Analysis of Correlation Coefficient Between Movements of Thoracoabdominal Tumors and External Respiration Using Image Guided Radiotherapy(IGRT) (영상유도 방사선치료장치(IGRT)를 이용한 흉·복부 종양의 움직임과 외부호흡과의 상관관계 분석)

  • Kim, Gha-Jung;Hong, Ju-Youn;Han, Sang-Hyun
    • The Journal of the Korea Contents Association
    • /
    • v.14 no.9
    • /
    • pp.362-370
    • /
    • 2014
  • This study measured and analyzed the correlation coefficient between movements of thoracoabdominal tumors and external respiration in a free-breathing state, using cyberknife image guided radiotherapy(IGRT). This study subjects included a total of 30 patients with lung tumors(n=10), liver tumors(n=10) and pancreatic tumor(n=10) who underwent radiotherapy, and the movements of tumors were analyzed using converted log data of the tumor motion tracking system(MTS). In a free-breathing state, In relation to Peason's correlation coefficient between external respiration and lung tumors in the entire treatment process, the correlation coefficient was 0.646(p<0.05) in the cranio-caudal direction, 0.365(p<0.088) in the left and right direction and 0.196(p<0.115) in the antero-posterior direction. The correlation coefficient of liver tumors was 0.841(p<0.000) in the cranio-caudal direction, 0.346 (p<0.179) in the left and right direction and 0.691(p<0.001) in the antero-posterior direction. The correlation coefficient of Pancreatic tumors was 0.683(p<0.000) in the cranio-caudal direction, 0.397(p<0.006) in the left and right direction and 0.268(p<0.127) in the antero-posterior direction. In conclusion, the measurement findings of thoracoabdominal tumor movement using IGRT would be helpful in determining an accurate target volume. Moreover, the analysis of correlation between external respiration and movements of internal tumors would provide important information to correct movements of tumors for diverse radiotherapy techniques.

Solid pseudopapillary epithelial neoplasm of pancreas in pregnancy: A case report and review of literature

  • R K Hanumantha Naik;Anbalagan Amudhan;ArunKumar Ashokkumar;Anbarasu Inbasekaran;Selvaraj Thangasamy;Jeswanth Sathyanesan
    • Annals of Hepato-Biliary-Pancreatic Surgery
    • /
    • v.28 no.1
    • /
    • pp.92-98
    • /
    • 2024
  • The solid pseudopapillary epithelial neoplasm (SPEN) of the pancreas is an uncommon tumor that accounts for approximately 1%-2% of exocrine pancreatic neoplasms. It predominantly affects female in their second and third decades of life. In this case report, we present a clinical scenario of a 21-year-old pregnant woman who incidentally discovered a solid cystic lesion in her pancreas, exhibiting features suggestive of SPEN. The patient underwent surgery during the second trimester. Management of pregnant females with SPEN poses challenges due to the absence of definitive treatment guidelines, particularly in determining the ideal timing for surgical intervention. Notably, during pregnancy, the presence of a small SPEN does not necessarily require immediate resection. However, if the tumor is of significant size, it can give rise to complications such as tumor rupture, multivisceral resection, recurrence, spontaneous abortion, intrauterine growth restriction, or premature delivery if not addressed. In the existing literature, a common finding is that approximately two-thirds of pregnant females with SPEN underwent surgery in the second trimester, often without complications for the mother or fetus. All these tumors were larger than 8 cm. The decision to operate before or after birth can be individualized based on team discussion. However, delay in surgery may lead to larger tumors and higher risks like bleeding, rupture, multivisceral resection, and recurrence. Therefore, second-trimester surgery seems safer, and lessens dangers, emergency surgery, and tumor recurrence.

Can Serum ICAM 1 Distinguish Pancreatic Cancer from Chronic Pancreatitis?

  • Mohamed, Amal;Saad, Yasmin;Saleh, Doaa;Elawady, Rehab;Eletreby, Rasha;Kharalla, Ahmed S.;Badr, Eman
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.10
    • /
    • pp.4671-4675
    • /
    • 2016
  • Background and aim: Pancreatic cancer is the fourth leading cause of cancer-related death worldwide, with an overall 5-year survival of <5% mainly due to presence of advanced disease at time of diagnosis. Therefore development of valid biomarkers to diagnose pancreatic cancer in early stages is an urgent need. This study concerned the sensitivity and specificity of serum ICAM 1 versus CA 19-9 in differentiation between pancreatic cancer and healthy subjects and acohort of patients with chronic pancreatitis with a focus on assessing validity in diagnosis of early stages of pancreatic cancer. Methods: A cohort of 50 patients with histologically diagnosed pancreatic tumors, 27 patients with chronic pancreatitis, and 35 healthy controls were enrolled. Serum samples for measurement of CA19-9 and I-CAM 1 were obtained from all groups and analyzed for significance regarding diagnosis and disease stage. Results: At a cut off value of (878.5 u/ml) I-CAM 1 had 82% and 82.26% sensitivity and specificity for differentiation between cancer and non-cancer cases, with higher sensitivity and specificity than CA19-9 at different cut offs (CA19-9 sensitivity and specificity ranged from 64-80% and 56.4 - 61.2% respectively). The AUC was 0.851 for I-CAM and 0.754 for CA19-9. Neither of the markers demonstrated significance for distinguishing between early and late cancer stages. Conclusion: ICAM 1 is a useful marker in differentiation between malignant and benign pancreatic conditions, and superior to CA19-9 in this regard. However, neither of the markers can be recommended for use in differentiation between early and late stage pancreatic cancers.

Case of Solitary Pancreatic Metastasis from Small Cell Lung Cancer

  • Park, Chul;Kim, Tae Hyeon;Yun, Ki Jung;Choi, Soon Ho;Lee, Sam Youn;Lee, Mi Kyung;Ryu, Dae Woong;Yang, Sei Hoon
    • Journal of Physiology & Pathology in Korean Medicine
    • /
    • v.26 no.6
    • /
    • pp.980-982
    • /
    • 2012
  • Metastasis to the pancreas from extra-pancreatic primary cancers are rare; they commonly present as a manifestation of widespread disease and rarely as an isolated mass of the pancreas. Examinations showed a pancreatic tumor infiltrating the pancreas tail portion and an endoscopic ultrasound guided percutaneous biopsy proved that the lesion was metastatic from the lung carcinoma. Most metastatic cases of the pancreas tend to be discovered in patients with widely disseminated malignant disease. In addition, patients with pancreatic metastasis are often asymptomatic, the metastatic lesions are found incidentally, and are misdiagnosed as primary pancreatic tumors. This report that patient undergoing chemotherapy for a small cell lung cancer, who 1 year and 3 months later, accidentally diagnosed of solitary pancreas metastasis and confirmed histology by needle biopsy using endoscopic ultrasound.

Treatment for Metastatic Pancreatic Cancer (전이성 췌장암의 치료)

  • Bo Young Lee;Sang Myung Woo
    • Journal of Digestive Cancer Research
    • /
    • v.6 no.2
    • /
    • pp.64-68
    • /
    • 2018
  • Pancreatic ductal adenocarcinoma is a dismal prognosis and 5th leading cause of cancer related death in Korea. A large proportion of patients are diagnosed at advanced or metastatic stage. Therefore systemic chemotherapy has become the mainstay of treatment for pancreatic cancer. For most patients advanced or metastatic pancreatic cancer that has a good Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1, we can recommend for FOLFIRINOX (leucovorin, 5-fluorouracil [5-FU], irinotecan and oxaliplatin) and gemcitabine plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Currently, steps towards improved therapeutic efficacy of palliative chemotherapy have been made by introducing these regimens. For patients with an ECOG PS of 2, gemcitabine monotherapy or S1 alone is recommended. The second-line therapy for patients initially treated with gemcitabine-based chemotherapy includes provide FOLFOX (leucovorin, 5-FU, and oxaliplatin), capecitabine plus oxaliplatin, and 5-FU plus liposomal irinotecan. The gemcitabine-based chemotherapy is a reasonable choice for patients treated with FOLFIRINOX. Currently, studies on selecting patients for biomarkers related to molecular biologic features of tumors are underway for the realization of precise medicine, and the development and verification of preclinical models for the development of new therapeutic agents are being carried out continuously.

  • PDF

Confocal Laser Endomicroscopy in the Diagnosis of Biliary and Pancreatic Disorders: A Systematic Analysis

  • Do Han Kim;Somashekar G. Krishna;Emmanuel Coronel;Paul T. Kroner;Herbert C. Wolfsen;Michael B. Wallace;Juan E. Corral
    • Clinical Endoscopy
    • /
    • v.55 no.2
    • /
    • pp.197-207
    • /
    • 2022
  • Background/Aims: Endoscopic visualization of the microscopic anatomy can facilitate the real-time diagnosis of pancreatobiliary disorders and provide guidance for treatment. This study aimed to review the technique, image classification, and diagnostic performance of confocal laser endomicroscopy (CLE). Methods: We conducted a systematic review of CLE in pancreatic and biliary ducts of humans, and have provided a narrative of the technique, image classification, diagnostic performance, ongoing research, and limitations. Results: Probe-based CLE differentiates malignant from benign biliary strictures (sensitivity, ≥89%; specificity, ≥61%). Needle-based CLE differentiates mucinous from non-mucinous pancreatic cysts (sensitivity, 59%; specificity, ≥94%) and identifies dysplasia. Pancreatitis may develop in 2-7% of pancreatic cyst cases. Needle-based CLE has potential applications in adenocarcinoma, neuroendocrine tumors, and pancreatitis (chronic or autoimmune). Costs, catheter lifespan, endoscopist training, and interobserver variability are challenges for routine utilization. Conclusions: CLE reveals microscopic pancreatobiliary system anatomy with adequate specificity and sensitivity. Reducing costs and simplifying image interpretation will promote utilization by advanced endoscopists.

Knockdown of Ezrin by RNA Interference Reverses Malignant Behavior of Human Pancreatic Cancer Cells in Vitro

  • Zhong, Zhi-Qiang;Song, Mao-Min;He, Ying;Cheng, Shi;Yuan, Hui-Sheng
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.8
    • /
    • pp.3781-3789
    • /
    • 2012
  • Background: Pancreatic cancer is one of the most aggressive tumors with a dismal prognosis. The membrane cytoskeletal crosslinker Ezrin participates in several functions including cell proliferation, adhesion, motility and survival. There is increasing evidence that Ezrin is overexpressed in vast majority of malignant tumors and regulates tumor progression. However, its roles in pancreatic cancer remain elusive. Methods: Three pairs of specific Ezrin siRNAs were designed and synthetized and screened to determine the most efficient one for construction of a hairpin RNA plasmid targeting Ezrin. After transfection into the Panc-1 pancreatic cancer cell line, real-time quantitative PCR and Western blotting were performed to examine the expression of mRNA and protein. The MTT method was applied to examine the proliferation and the drug sensibility to Gemcitabine. Flow cytometry was used to assess the cycle and apoptosis, while capacity for invasion was determined with transwell chambers. Furthermore, we detected phosphorylated-Erk1/2 protein and phosphorylated-Akt protein by Western blotting. Results: Real-time quantitative PCR and Western blotting revealed that Ezrin expression was notably down-regulated at both mRNA and protein levels by RNA interference (P< 0.01). Proliferation was inhibited and drug resistance to gemcitabine was improved (P< 0.05). Flow cytometry showed that the proportion of cells in the G1/G0 phase increased (P< 0.01), and in G2/M and S phases decreased (P< 0.05), with no apparent differences in apoptosis (P> 0.05). The capacity for invasion was markedly reduced (P< 0.01). In addition, down-regulating Ezrin expression had no effect on phosphorylated-Akt protein (P>0.05), but could decrease the level of phosphorylated-Erk1/2 protein (P< 0.05). Conclusions: RNA interference of Ezrin could inhibit its expression in the pancreatic cancer cells line Panc-1, leading to a potent suppression of malignant behavior in vitro. Assessment of potential as a target for pancreatic cancer treatment is clearly warranted.